Ventyx Biosciences (NASDAQ:VTYX) Price Target Cut to $11.00

Ventyx Biosciences (NASDAQ:VTYX) had its target price trimmed by Wells Fargo & Company from $16.00 to $11.00 in a research report released on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities analysts have also weighed in on VTYX. HC Wainwright reiterated a neutral rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Tuesday, July 30th. Oppenheimer lowered their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an outperform rating on the stock in a report on Thursday, June 6th. Finally, Canaccord Genuity Group lowered their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a buy rating on the stock in a report on Monday. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences presently has a consensus rating of Moderate Buy and an average target price of $8.29.

Ventyx Biosciences Trading Up 0.5 %

Shares of NASDAQ VTYX opened at $1.92 on Monday. The firm’s 50-day moving average price is $2.49 and its 200-day moving average price is $4.14. Ventyx Biosciences has a 1-year low of $1.87 and a 1-year high of $38.20. The firm has a market capitalization of $135.36 million, a P/E ratio of -0.59 and a beta of 0.39.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.12. Equities research analysts forecast that Ventyx Biosciences will post -2.31 EPS for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTYX. Bleakley Financial Group LLC purchased a new stake in Ventyx Biosciences in the 4th quarter valued at about $81,000. Simplicity Solutions LLC bought a new position in shares of Ventyx Biosciences during the 4th quarter valued at approximately $81,000. Federated Hermes Inc. bought a new position in shares of Ventyx Biosciences during the 4th quarter valued at approximately $50,000. Jump Financial LLC bought a new position in shares of Ventyx Biosciences during the 4th quarter valued at approximately $72,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Ventyx Biosciences during the 4th quarter valued at approximately $323,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.